Shenzhen Weiguang Biological Products Past Earnings Performance
Past criteria checks 5/6
Shenzhen Weiguang Biological Products has been growing earnings at an average annual rate of 4.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.2% per year. Shenzhen Weiguang Biological Products's return on equity is 11.4%, and it has net margins of 21.4%.
Key information
4.2%
Earnings growth rate
4.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 5.2% |
| Return on equity | 11.4% |
| Net Margin | 21.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shenzhen Weiguang Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,167 | 250 | 132 | 51 |
| 30 Jun 24 | 1,114 | 227 | 129 | 66 |
| 31 Mar 24 | 1,066 | 220 | 131 | 65 |
| 31 Dec 23 | 1,049 | 219 | 124 | 64 |
| 30 Sep 23 | 992 | 196 | 109 | 58 |
| 30 Jun 23 | 893 | 172 | 104 | 40 |
| 31 Mar 23 | 739 | 138 | 91 | 36 |
| 01 Jan 23 | 668 | 118 | 90 | 36 |
| 30 Sep 22 | 702 | 141 | 83 | 41 |
| 30 Jun 22 | 803 | 182 | 88 | 42 |
| 31 Mar 22 | 907 | 204 | 89 | 49 |
| 01 Jan 22 | 907 | 205 | 90 | 48 |
| 30 Sep 21 | 914 | 207 | 89 | 51 |
| 30 Jun 21 | 833 | 183 | 80 | 47 |
| 31 Mar 21 | 854 | 186 | 83 | 49 |
| 31 Dec 20 | 905 | 190 | 80 | 45 |
| 30 Sep 20 | 895 | 183 | 91 | 46 |
| 30 Jun 20 | 868 | 178 | 91 | 43 |
| 31 Mar 20 | 842 | 176 | 82 | 35 |
| 31 Dec 19 | 821 | 171 | 81 | 40 |
| 30 Sep 19 | 753 | 158 | 66 | 27 |
| 30 Jun 19 | 749 | 158 | 66 | 30 |
| 31 Mar 19 | 726 | 159 | 70 | 29 |
| 31 Dec 18 | 688 | 157 | 71 | 24 |
| 30 Sep 18 | 651 | 156 | 75 | 26 |
| 30 Jun 18 | 610 | 148 | 60 | 34 |
| 31 Mar 18 | 606 | 145 | 63 | 31 |
| 31 Dec 17 | 623 | 155 | 65 | 26 |
| 30 Sep 17 | 574 | 144 | 65 | 18 |
| 30 Jun 17 | 592 | 154 | 80 | 0 |
| 31 Mar 17 | 577 | 154 | 96 | 0 |
| 31 Dec 16 | 566 | 153 | 78 | 0 |
| 30 Jun 16 | 513 | 132 | 68 | 0 |
| 31 Mar 16 | 501 | 125 | 48 | 0 |
| 31 Dec 15 | 501 | 125 | 65 | 0 |
| 31 Dec 14 | 453 | 101 | 55 | 0 |
| 31 Dec 13 | 355 | 89 | 59 | 0 |
Quality Earnings: 002880 has high quality earnings.
Growing Profit Margin: 002880's current net profit margins (21.4%) are higher than last year (19.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002880's earnings have grown by 4.2% per year over the past 5 years.
Accelerating Growth: 002880's earnings growth over the past year (27.6%) exceeds its 5-year average (4.2% per year).
Earnings vs Industry: 002880 earnings growth over the past year (27.6%) exceeded the Biotechs industry 0.08%.
Return on Equity
High ROE: 002880's Return on Equity (11.4%) is considered low.